PCSK9 Mediates Dyslipidemia Induced by Olanzapine Treatment in Schizophrenia Patients

Guide for the Care and Use of Laboratory Animals: Eighth Edition

(2011) · doi:10.17226/12910 · Cited by 16,199 · see citing works

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985 · see citing works

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · see citing works

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930 · see citing works

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753 · see citing works

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S., & Goldstein, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1534923100 · Cited by 1,427 · see citing works

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · see citing works

Excess early mortality in schizophrenia.

Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153657 · Cited by 913 · cited 1× · see citing works

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking <i>Pcsk9</i>

Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679 · see citing works

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

Maxwell, K. N., & Breslow, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402133101 · Cited by 613 · see citing works

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 575 · see citing works

A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol

Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517 · see citing works

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells

Lagace, T. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000114 · Cited by 372 · see citing works

Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c

Costet, P., Cariou, B., Lambert, G. C., Lalanne, F., Lardeux, B. R., Jarnoux, A. L., Grefhorst, A., Staels, B., & Krempf, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508582200 · Cited by 305 · see citing works

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk

Humphries, S. E., Whittall, R. A., Hubbart, C. S., Maplebeck, S., Cooper, J. A., Soutar, A. K., Naoumova, R., Thompson, G. R., Seed, M., Durrington, P. N., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.038356 · Cited by 267 · see citing works

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

Abifadel, M., Rabès, J., Devillers, M., Münnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C. (2009) · Human Mutation · doi:10.1002/humu.20882 · Cited by 255 · see citing works

Hepatic Insulin Signaling Is Required for Obesity-Dependent Expression of SREBP-1c mRNA but Not for Feeding-Dependent Expression

Haas, J. T., Miao, J., Chanda, D., Wang, Y., Zhao, E., Haas, M. E., Hirschey, M. D., Vaitheesvaran, B., Farese, R. V., Kurland, I. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.002 · Cited by 207 · see citing works

Review: Mortality in schizophrenia: a measurable clinical endpoint

Bushe, C. J., Taylor, M., & Haukka, J. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382468 · Cited by 185 · see citing works

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cinì, E., Rossi, M., McCormick, P., Corsini, G., Maggio, R., & Scarselli, M. (2018) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 182 · see citing works

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

Cariou, B., Langhi, C., Bras, M. L., Bortolotti, M., Lê, K., Theytaz, F., May, C. L., Guyomarch, B., Zaïr, Y., Kreis, R., et al. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-4 · Cited by 109 · see citing works

Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials

Wu, R., Zhang, F.-Y., Gao, K.-M., Ou, J.-J., Shao, P., Jin, H., Guo, W.-B., Chan, P. K., & Zhao, J.-P. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.221 · Cited by 72 · see citing works

Insulin resistance and metabolic profile in antipsychotic naïve schizophrenia patients

Dasgupta, A., Singh, O. P., Rout, J. K., Saha, T., & Mandal, S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.011 · Cited by 62 · see citing works

Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment

Tomasik, J., Lago, S. G., Vázquez-Bourgón, J., Papiol, S., Suárez‐Pinilla, P., Crespo‐Facorro, B., & Bahn, S. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0304 · Cited by 59 · see citing works

Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT 2A receptor agonism

Aringhieri, S., Kolachalam, S., Gerace, C., Carli, M., Verdesca, V., Brunacci, M. G., Rossi, C., Ippolito, C., Solini, A., Corsini, G. U., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.02.005 · Cited by 46 · see citing works

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients

Huang, J., Hei, G., Yang, Y., Liu, C., Xiao, J., Long, Y., Peng, X., Yang, Y., Zhao, J., & Wu, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00739 · Cited by 45 · see citing works

Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis

Li, R., Zhang, Y., Zhu, W., Ding, C., Dai, W., Su, X., Dai, W., Xiao, J., Xing, Z., & Huang, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-73983-4 · Cited by 43 · see citing works

New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China☆

Hu, D. (2016) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2016.11.001 · Cited by 30 · see citing works

Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats

Liu, X., Deng, C., Cao, S., Gong, J., Wang, B., & Hu, C. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.01.033 · Cited by 27 · see citing works

Assessment of lipid response to acute olanzapine administration in healthy adults

Nahmias, A., Stahel, P., & Dash, S. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.119 · Cited by 5 · see citing works

Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers

Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., et al. (2024) · Metabolites · doi:10.3390/metabo14020080 · Cited by 36 · see citing works

Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway

Zhu, W., Ding, C., Huang, P., Ran, J., Lian, P., Tang, Y., Dai, W., & Huang, X. (2022) · Scientific Reports · doi:10.1038/s41598-022-09610-1 · Cited by 27 · see citing works

Antipsychotic-Induced Alterations in Lipid Turnover

Pereira, S., Au, E., Agarwal, S. M., Wright, D. C., & Hahn, M. (2023) · Endocrinology · doi:10.1210/endocr/bqad025 · Cited by 22 · see citing works

Drug–drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs

Buzea, A., Manu, P., Dima, L., & Correll, C. U. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2147425 · Cited by 19 · see citing works

Atypical antipsychotic drugs cause abnormal glucose and lipid metabolism independent of weight gain

Yang, Y., & Wu, R. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-01965-6 · Cited by 10 · see citing works

Uric acid and HDL-C-derived inflammatory ratios as biomarkers in schizophrenia and major depressive disorder: a retrospective study

Chen, H., Qiu, M., Zhang, H., Huai, Y., Huang, Q., Li, P., Lei, Y., Jiang, Y., Li, Q., & Zhang, S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1698455 · Cited by 3 · see citing works

Effects of statin therapies on individuals taking antipsychotics: a systematic review

Ferrell, M. C., Ernst, Z., Ferrell, S. C., Jaiswal, D. D., & Vassar, M. B. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001489 · Cited by 3 · see citing works

Research progress in the correlation between SREBP/PCSK9 pathway and lipid metabolism disorders induced by antipsychotics.

Ma, J., Zheng, Y., Sun, F., Fan, Y., Fan, Y., Su, X., Wang, Z., Weng, N., & Li, R. (2023) · PubMed Central · doi:10.11817/j.issn.1672-7347.2023.230029 · Cited by 3 · see citing works

Screening of the Key Genes and Signaling Pathways for Schizophrenia Using Bioinformatics and Next Generation Sequencing Data AnalysisPreprint

Vastrad, B. M., & Vastrad, C. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.24.563759 · Cited by 2 · see citing works

Screening of the key genes and signaling pathways for schizophrenia using bioinformatics and next generation sequencing data analysis

Kotturshetti, I., Vastrad, B. M., Kori, V., Vastrad, C. M., & Kotrashetti, S. (2024) · Italian Journal of Medicine · doi:10.4081/itjm.2024.1830 · Cited by 3 · see citing works

Real-World Evidence on Low-Dose Olanzapine (≤1.25 mg) for Personalized Antipsychotic Dosing

Kang, D., Moon, S., Baek, J. H., & Cho, J. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080380 · Cited by 1 · see citing works

Cell models to probe the biological bases of antipsychotic-induced metabolic Syndrome: towards an individual specific approach

Fiore, M., Saltarelli, S., Mastro, L. D., D’Ambrosio, E., Ianniello, A., Bertolino, A., Pergola, G., Favia, M., & Rampino, A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110814 · Cited by 1 · see citing works

Protective effects of menthol against olanzapine-induced metabolic alterations in female mice

Sodhi, R. K., Kumar, H., Singh, R., Bansal, Y., Kondepudi, K. K., Bishnoi, M., & Kuhad, A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177010

Olanzapine-induced metabolic syndrome is partially mediated by oxytocinergic system dysfunction in female Sprague-Dawley rats

Oduor, E. D., Mwangi, P. W., Chege, B. M., Olago, S. F., & Bukachi, F. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334966

Systematic Study to Unveil Novel Biomarkers, Regulatory Pathways and Exploring Therapeutic Targets for Schizophrenia Using Next Generation Sequencing Data Analysis and In Silico Drug DesignPreprint

Vastrad, B. M., Pattanashetti, S., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-8284834/v1

PCSK9 at the intersection of lipid metabolism, immunometabolism, and psychiatric disorders: A narrative review

van Bruggen, F. H., & McIntyre, R. S. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101289

Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis

Li, R., Zhang, Y., Zhu, W., Ding, C., Dai, W., Su, X., Dai, W., Xiao, J., Xing, Z., & Huang, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-73983-4 · Cited by 43 · see citing works

Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia

Ono, S., & Someya, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_402 · Cited by 4 · see citing works

Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study

Smith, R. C., Lindenmayer, J., Hu, Q., Kelly, E., Viviano, T. F., Cornwell, J., Vaidhyanathaswamy, S., Marcovina, S. M., & Davis, J. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.001 · Cited by 35 · see citing works

Activation of the PERK-CHOP signaling pathway during endoplasmic reticulum stress contributes to olanzapine-induced dyslipidemia

Liu, L., Tang, L., Luo, J., Chen, S., Yi, C.-Y., Liu, X., & Hu, C. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01180-w · Cited by 15 · see citing works

Untitled work

(2004) · PubMed · Cited by 108 · see citing works